Breaking Finance News

Abbott Laboratories Reports Strong Q2 Earnings (ABT)

Abbott Laboratories (NYSE: ABT) reported second quarter EPS of $0.46 versus consensus estimates $0.44.  EPS were Up 7 percent year over year. Revenue came in at $5.45 billion versus estimates of $5.52 billion. Sales were Down 44 percent year over year.

In the release, the company said,

  • Second-quarter adjusted diluted EPS was $0.46, above the previous guidance range; reported diluted EPS from continuing operations under GAAP was $0.30.
  • Abbott is confirming its full-year 2013 EPS guidance, representing double-digit growth.
  • Excluding foreign exchange, worldwide sales increased 4.2 percent. Reported sales increased 2.5 percent, including an unfavorable 1.7 percent effect of foreign exchange. Sales were driven by 8.4 percent operational sales growth in Nutrition, including 18.4 percent international growth, and 7.6 percent operational sales growth in Diagnostics.
  • Abbott continued to expand its presence in emerging markets across all business segments. Emerging market sales were $2.3 billion in the second quarter, an increase of 13.4 percent on an operational basis.
  • Second-quarter adjusted gross margin ratio of 55.0 percent exceeded previous expectations, driven by strong momentum in Nutrition and Diagnostics. The gross margin ratio under GAAP was 49.7 percent.
  • Abbott launched several new products and initiated new clinical trials in the second quarter. Highlights include 24 new product launches in Nutrition; the first FDA-approved hepatitis C virus (HCV) genotyping test; the initiation of a randomized clinical trial in Japan for Abbott’s bioresorbable vascular scaffold, Absorb; the approval of XIENCE Xpedition in Japan; and the U.S. approval and launch of the TECNIS® Toric 1-Piece Intraocular Lens (IOL) for cataract patients with astigmatism.
  • On July 15, Abbott announced two acquisitions in its Medical Devices business: IDEV Technologies, which expands Abbott’s endovascular portfolio, and OptiMedica, which provides an immediate entry point into the laser cataract surgery market.

[stock-tools exchange="NYSE" symbol="ABT" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.